Cardioprotective effects of melatonin and metformin against doxorubicin-induced cardiotoxicity in rats are through preserving mitochondrial function and dynamics

• Published in: Biochemical pharmacology 2021-10, Vol.192, p.114743, Article 114743
• Main Authors: Arinno, Apiwan, Maneechote, Chayodom, Khuanjing, Thawatchai, Ongnok, Benjamin, Prathumsap, Nanthip, Chunchai, Titikorn, Arunsak, Busarin, Kerdphoo, Sasiwan, Shinlapawittayatorn, Krekwit, Chattipakorn, Siriporn C., Chattipakorn, Nipon
• Format: Article
• Language: English
• Subjects: Animals; Antibiotics, Antineoplastic - toxicity; Cardiotonic Agents - pharmacology; Cardiotonic Agents - therapeutic use; Cardiotoxicity - metabolism; Cardiotoxicity - prevention & control; Cell Line; Dose-Response Relationship, Drug; Doxorubicin - toxicity; Doxorubicin-induced cardiotoxicity; Heart; Male; Melatonin; Melatonin - pharmacology; Melatonin - therapeutic use; Metformin; Metformin - pharmacology; Metformin - therapeutic use; Mitochondria; Mitochondria - drug effects; Mitochondria - metabolism; Mitochondrial Dynamics - drug effects; Mitochondrial Dynamics - physiology; Myocytes, Cardiac - drug effects; Myocytes, Cardiac - metabolism; Rats; Rats, Wistar
• ISSN: 0006-2952; 1873-2968
• DOI: 10.1016/j.bcp.2021.114743

[Display omitted] Doxorubicin (Dox) is widely used in chemotherapy regimens for several malignant conditions. Unfortunately, cumulative and irreversible cardiotoxicity of Dox is the most prominent adverse effect which limits its use. Several pharmacological interventions which exert antioxidant properties, including melatonin and metformin, have demonstrated beneficial effects against various cardiac pathological conditions. However, the exact molecular mechanisms underlying their cardioprotective effects are not completely understood. We hypothesized that treatment with either melatonin or metformin provides cardioprotection against Dox-induced cardiotoxicity through mitochondrial protection. Thirty-two male Wistar rats received 6 doses of either 0.9% normal saline solution (0.9% NSS, n = 8) or Dox (3 mg/kg, i.p., n = 24). The Dox-treated rats (n = 8/group) were co-treated with: 1) Vehicle (0.9% NSS), 2) Melatonin (10 mg/kg/day), and 3) Metformin (250 mg/kg/day) for 30 consecutive days via oral gavage. Following the treatment, left ventricular (LV) function, oxidative stress, inflammation, mitochondrial function, dynamics, biogenesis and bioenergetics, mitophagy, autophagy, and apoptosis were determined. Dox induced excessive oxidative stress, inflammation, autophagy, apoptosis, reduced mitochondrial function, dynamics balance, biogenesis, and bioenergetics leading to LV dysfunction. Treatment with either melatonin or metformin exerted equal measures of cardioprotection via reducing oxidative stress, inflammation, autophagy, apoptosis, and improved mitochondrial function, dynamics balance, biogenesis, and bioenergetics in the Dox-treated rats. Melatonin and metformin exerted both anti-cancer and cardioprotective properties, suggesting they have potential roles in concomitant therapy in cancer patients receiving Dox treatment.